Pharmacological CDK4/6 inhibition promotes vulnerability to lysosomotropic agents in breast cancer
Ontology highlight
ABSTRACT: Breast cancer is a leading cause of mortality worldwide. Pharmacological inhibitors of Cyclin-Dependent Kinases (CDK) 4 and 6 (CDK4/6i) inhibit breast cancer growth by inducing a senescent-like state. However, long-term treatment efficacy remains hindered by the development of drug resistance. Clearance of senescent-like cancer cells may extend the durability of treatment. In this study, we showed that CDK4/6i-treated breast cancer cells exhibit various senescence-associated phenotypes, but remain insensitive to common senolytic compounds. By searching for novel vulnerabilities, we identified a significantly increased lysosomal mass and altered lysosomal structure across various breast cancer cell types upon exposure to CDK4/6i in preclinical systems and clinical specimens. We demonstrated
SUBMITTER: Jamil Nehme
PROVIDER: S-SCDT-10_1038-S44318-025-00371-X | biostudies-other |
REPOSITORIES: biostudies-other
ACCESS DATA